International Journal of Oral Biology

The Korean Academy of Oral Biology (대한구강생물학회)
권호 표지

The enhancement of apoptosis by combined with proteasome inhibitor and DNA synthetic inhibitor in oral cancer

  • Lee, Young-Hee (Department of Oral biochemistry, School of Dentistry and Institute of Oral-bio Science, Chonbuk National University) ;
  • Jung, Ji-Eun (Department of Oral biochemistry, School of Dentistry and Institute of Oral-bio Science, Chonbuk National University) ;
  • Lee, Jung-Chang (Department of Oral biochemistry, School of Dentistry and Institute of Oral-bio Science, Chonbuk National University) ;
  • Moon, Hyun-Ju (Department of Oral biochemistry, School of Dentistry and Institute of Oral-bio Science, Chonbuk National University) ;
  • Lee, Nan-Hee (Department of Oral biochemistry, School of Dentistry and Institute of Oral-bio Science, Chonbuk National University) ;
  • Jhee, Eun-Jung (Department of Oral biochemistry, School of Dentistry and Institute of Oral-bio Science, Chonbuk National University) ;
  • Yi, Ho-Keun (Department of Oral biochemistry, School of Dentistry and Institute of Oral-bio Science, Chonbuk National University)
  • Published : 2008.03.31
Download PDF
⟨ Previous Next ⟩

Abstract

Inhibition of proteasome activity may reduce many types of cancer, so it's pathway is effective in cancer as well as in clinical fields. Here the author has carried out experiment targeting on the elevation of apoptosis in oral cancer cells by combination of proteasome inhibitor, lactacystin, and DNA replication inhibitor, etoposide. The growth of KB cells was measured by MTT methods and apoptosis was analyzed by DNA fragmentation and Hochest nucleus staining. The proteasome activity was analyzed by fluorescent tagged peptide and cellular protein expression was detected by Western hybridization. Though lactacystin and etoposide inhibited KB cell growth alone, but low combined doses inhibited cell growth more strongly and induced apoptosis. The proteasome activity was also seriously inhibited by the combination of both chemicals. Tumor suppressor proteins and apoptosis inducing proteins were highly increased under the combination of both chemicals. From above studies we can conclude that proteasome inhibitors may be used for the treatment of oral cancer and proteasome inhibitors with DNA replication inhibitors may be effective in clinical trials of oral cancer.

Keywords

References

  1. Adachi, N., Suzuki, H., Iiizumi, S., Koyama, H.: Hypersensitivity of nonhomologous DNA end-joining mutants to VP-16 and ICRF-193: implications for the repair of topoisomerase II mediated DNA damage. J Biol Chem. 278:35897-35902, 2003 https://doi.org/10.1074/jbc.M306500200
  2. Adams, J., Palombella, V.J., Sausville, E.A., Johnson, J., Destree, A., Lazarus, D.D., Maas, J., Pien, C.S., Prakash, S., Elliott, P. J.: Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res. 59:2615-2622, 1999
  3. Adams, J.: The proteasome: structure, function, and role in the cell. Cancer Treatment Rev. 29:3-9, 2003
  4. Aghajanian, C., Soignet, S., Dizon, D.S., Pien, C.S., Adams, J., Elliott, P.J., Sabbatini, P., Miller, V., Hensley, M.L., Pezzulli, S., Canales, C., Daud, A., Spriggs, D.R.: A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin Cancer Res. 8:2505-2511, 2002
  5. An, W. G., Hwang, S.G., Trepel, J.B., Blagosklonny, M.V.: Protease inhibitor-induced apoptosis: accumulation of wt p53, p21WAF1/CIP1, and induction of apoptosis are independent markers of proteasome inhibition. Leukemia. 14:1276-1283, 2000 https://doi.org/10.1038/sj.leu.2401812
  6. Banerjee, D., Liefshitz, A.: Potential of the proteasomal inhibitor MG-132 as an anticancer agent, alone and in combination. Anticancer Res. 21:3941-3947, 2001
  7. Bross, P.F., Kane, R., Farrell, A.T., Abraham, S., Benson, K., Brower, M.E., Bradley, S., Gobburu, J.V., Goheer, A., Lee, S.L., Leighton, J., Liang, C.Y., Lostritto, R.T., McGuinn, W.D., Morse, D.E., Rahman, A., Rosario, L.A., Verbois, S.L., Williams, G., Wang, Y.C., Pazdur, R.: Approval summary for bortezomib for injection in the treatment of multiple myeloma. Clin Cancer Res. 10:3954-3964, 2004 https://doi.org/10.1158/1078-0432.CCR-03-0781
  8. Ciechanover, A.: The ubiquitin-proteasome pathway. Cell 79:13-21, 1994 https://doi.org/10.1016/0092-8674(94)90396-4
  9. Cusack, J. C. Jr., Liu, R., Houston, M., Abendroth, K., Elliott, P. J., Adams, J., Baldwin, A. S. Jr.: Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition. Cancer Res. 61:3535-3540, 2001
  10. Frankel, A., Man, S., Elliott, P., Adams, J., Kerbel, R.S.: Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341. Clin Cancer Res. 6:3719-3728, 2000
  11. Hideshima, T., Richardson, P., Chauhan, D., Palombella, V.J., Elliott, P.J., Adams, J., Anderson, K.C.: The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 61:3071-3076, 2001
  12. Jeremias, I., Kupatt, C., Baumann, B., Herr, I., Wirth, T., Debatin, K.M.: Inhibition of nuclear factor kappaB activation attenuates apoptosis resistance in lymphoid cells. Blood. 91:4624-4631, 1998
  13. LeBlanc, R., Catley, L.P., Hideshima, T., Lentzsch, S., Mitsiades, C.S., Mitsiades, N., Neuberg, D., Goloubeva, O., Pien, C.S., Adams, J., Gupta, D., Richardson, P.G., Munshi, NC., Anderson, K.C.: Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res. 62:4996-5000, 2002
  14. Licitra, L., Grandi, C., Prott, F.J., Schornagel, J.H., Bruzzi, P., Molinari, R.: Major and minor salivary glands tumours. Crit Rev Oncol Hematol. 45:215-225, 2003 https://doi.org/10.1016/S1040-8428(02)00005-7
  15. Lonial, S., Waller, E. K., Richardson, P. G., Jagannath, S., Orlowski, R. Z., Giver, C. R., Jaye, D. L., Francis, D., Giusti, S., Torre, C., Barlogie, B., Berenson, J. R., Singhal, S., Schenkein, D. P., Esseltine, D.L., Anderson, J., Xiao, H., Heffner, L.T., Anderson, K. C.: Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma. Blood. 106:3777-3784, 2005 https://doi.org/10.1182/blood-2005-03-1173
  16. Omura, S., Matsuzakim K., Fujimoto, T., Kosuge, K., Furuya, T., Fujita, S., Nakagawa, A.: Structure of lactacystin, a new microbial metabolite which induces differentiation of neuroblastoma cells. J Antibiot. 44:117-118, 1991 https://doi.org/10.7164/antibiotics.44.117
  17. Pickart, C.M.: Mechanisms underlying ubiquitination. Annu Rev Biochem. 70:503-533, 2001 https://doi.org/10.1146/annurev.biochem.70.1.503
  18. Roccaro, A. M., Hideshima, T., Raje, N., Kumar, S., Ishitsuka, K., Yasui, H., Shiraishi, N., Ribatti, D., Nico, B., Vacca, A., Dammacco, F., Richardson, P.G., Anderson, K.C.: Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells. Cancer Res. 66:184-191, 2006 https://doi.org/10.1158/0008-5472.CAN-05-1195
  19. Samuels-Lev, Y., O'Connor, D.J., Bergamaschi, D., Trigiante, G., Hsieh, J.K., Zhong, S., Campargue, I., Naumovski, L., Crook, T., Lu, X.: ASPP proteins specifically stimulate the apoptotic function of p53. Mol Cell. 8:781-794, 2001 https://doi.org/10.1016/S1097-2765(01)00367-7
  20. Shah, S.A., Potter, M.W., McDade, T.P., Ricciardi, R., Perugini, R. A., Elliott, P. J., Adams, J., Callery, M. P.: 26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer. J Cell Biochem. 82:110-122, 2001 https://doi.org/10.1002/jcb.1150
  21. Sun, Y.: Targeting E3 ubiquitin ligases for cancer therapy. Cancer Biol Ther. 2:623-629, 2003
  22. Van de Loosdrecht, A. A., Nennie, E., Ossenkoppele, G. J., Beelen, R. H. J., Lngenhuijsen, M. M. A. C.: Cell mediated cytotoxicity against U937 cells by human monocytes and macrophages in modified colorimetric MTT assay. J Immunol Methods. 141:15-22, 1991 https://doi.org/10.1016/0022-1759(91)90205-T
  23. Wojcik, C.: Proteasomes in apoptosis: Villains or guardians? Cell Mol Life Sci. 56:908-917, 1999 https://doi.org/10.1007/s000180050483